|
TOP
|
|
APTIVUS®(二十五)
navir/ritonavir;
No Effect = 1.00
|
|
Cmax |
AUC |
Cmin |
a HIV-1 positive patients
b Buprenorphine/Naloxone maintenance patients
c HIV-1 positive patients (tipranavir/ritonavir 250 mg/200 mg, 750 mg/200 mg and 1250 mg/100 mg) and healthy volunteers (tipranavir/ritonavir 500 mg/100 mg and 750 mg/200 mg)
d Normalized sum of parent drug (rifabutin) and active metabolite (25-O-desacetyl-rifabutin)
e Intensive PK analysis
f Drug levels obtained at 8-16 hrs post-dose
↑ increase, ↓ decrease, ↔ no change, ↕ unable to predict |
|
Amprenavir/ritonavira |
600/100 mg BID
(27 doses) |
500/200 mg BID
(28 doses) |
16
74 |
↓
↓ |
0.61 (0.51, 0.73)e |
0.56 (0.49, 0.64)e
- |
0.45 (0.38, 0.53)e
0.44 (0.39, 0.49)f |
|
Abacavira |
300 mg BID
(43 doses) |
250/200 mg BID
750/100 mg BID
1250/100 mg BID
(42 doses) |
28
14
11 |
↓
↓
↓ |
0.56 (0.48, 0.66)
0.54 (0.47, 0.63)
0.48 (0.42, 0.53) |
0.56 (0.49, 0.63)
0.64 (0.55, 0.74)
0.65 (0.55, 0.76) |
-
-
- |
|
Atazanavir/ritonavir |
300/100 mg QD
(9 doses) |
500/100 mg BID
(34 doses) |
13 |
↓ |
0.43 (0.38, 0.50) |
0.32 (0.29, 0.36) |
0.19 (0.15, 0.24) |
|
Atorvastatin |
10 mg
(1 dose) |
500/200 mg BID
(17 doses) |
22 |
↑ |
8.61 (7.25, 10.21) |
9.36 (8.02, 10.94) |
5.19 (4.21, 6.40) |
|
Orthohydroxy-atorvastatin |
|
21, 12, 17 |
↓ |
0.02 (0.02, 0.03) |
0.11 (0.08, 0.17) |
0.07 (0.06, 0.08) |
|
Parahydroxy-atorvastatin |
|
13, 22, 1 |
↓ |
1.04 (0.87, 1.25) |
0.18 (0.14, 0.24) |
0.33 (NA) |
Buprenorphine/
Naloxoneb |
16/4 mg
24/6 mg
(daily) |
500/200 mg BID
(16 doses) |
|
|
|
|
|
|
Buprenorphine |
|
|
10 |
↔ |
0.86 (0.68, 1.10) |
0.99 (0.80, 1.23) |
0.94 (0.74, 1.19) |
|
Carbamazepine |
100 mg BID
(29 doses) |
500/200 mg
(1 dose) |
7 |
↔ |
1.04 (1.00, 1.07) |
1.05 (1.02, 1.09) |
1.17 (1.11, 1.24) |
|
|
|
|
(43 doses) |
(15 doses) |
7 |
↔ |
1.10 (0.85, 1.42) |
1.08 (0.91, 1.27) |
1.07 (0.90, 1.27) |
|
|
200 mg BID
(29 doses) |
500/200 mg
(1 dose) |
17 |
↔ |
1.00 (0.96, 1.04) |
1.04 (1.00, 1.08) |
1. |
|
